-$1.91 EPS Expected for Spark Therapeutics, Inc. (NASDAQ:ONCE) This Quarter
Analysts expect Spark Therapeutics, Inc. (NASDAQ:ONCE) to post ($1.91) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Spark Therapeutics’ earnings, with the highest EPS estimate coming in at ($1.75) and the lowest estimate coming in at ($2.05). Spark Therapeutics posted earnings of ($1.07) per share during the same quarter last year, which suggests a negative year over year growth rate of 78.5%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 2nd.
On average, analysts expect that Spark Therapeutics will report full year earnings of ($7.36) per share for the current year, with EPS estimates ranging from ($8.00) to ($6.77). For the next fiscal year, analysts expect that the business will post earnings of ($5.25) per share, with EPS estimates ranging from ($7.92) to ($3.01). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Spark Therapeutics.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the consensus estimate of ($1.75) by $0.14. The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The business’s revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.04) earnings per share.
Several equities analysts recently issued reports on the company. Jefferies Group LLC assumed coverage on Spark Therapeutics in a research note on Monday, July 10th. They set a “buy” rating and a $85.00 target price on the stock. Cantor Fitzgerald set a $94.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a research note on Monday, July 17th. ValuEngine lowered Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 20th. BidaskClub raised Spark Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Finally, Zacks Investment Research raised Spark Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company’s stock. Spark Therapeutics presently has an average rating of “Buy” and an average price target of $82.27.
In other Spark Therapeutics news, CFO Stephen W. Webster sold 7,663 shares of the stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $60.00, for a total value of $459,780.00. Following the sale, the chief financial officer now owns 10,163 shares of the company’s stock, valued at approximately $609,780. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jeffrey D. Marrazzo sold 28,650 shares of the stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $80.01, for a total value of $2,292,286.50. Following the completion of the sale, the chief executive officer now directly owns 258,650 shares in the company, valued at approximately $20,694,586.50. The disclosure for this sale can be found here. Insiders sold a total of 314,310 shares of company stock worth $21,866,838 in the last ninety days. 7.30% of the stock is owned by corporate insiders.
A number of large investors have recently bought and sold shares of ONCE. FMR LLC raised its stake in Spark Therapeutics by 0.9% in the first quarter. FMR LLC now owns 4,656,655 shares of the biotechnology company’s stock worth $248,386,000 after buying an additional 40,698 shares in the last quarter. BlackRock Inc. raised its stake in Spark Therapeutics by 11,332.0% in the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock worth $98,158,000 after buying an additional 1,824,117 shares in the last quarter. Vanguard Group Inc. raised its stake in Spark Therapeutics by 5.2% in the first quarter. Vanguard Group Inc. now owns 1,827,660 shares of the biotechnology company’s stock worth $97,487,000 after buying an additional 90,686 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Spark Therapeutics by 7.8% in the first quarter. JPMorgan Chase & Co. now owns 1,549,093 shares of the biotechnology company’s stock worth $82,628,000 after buying an additional 112,596 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Spark Therapeutics by 119.5% in the first quarter. Wellington Management Group LLP now owns 808,782 shares of the biotechnology company’s stock worth $43,140,000 after buying an additional 440,287 shares in the last quarter. 88.96% of the stock is currently owned by institutional investors.
Spark Therapeutics (NASDAQ:ONCE) traded up 0.14% during mid-day trading on Friday, hitting $76.96. The company had a trading volume of 2,519,357 shares. The company’s market capitalization is $2.38 billion. The company has a 50-day moving average price of $63.15 and a 200 day moving average price of $58.70. Spark Therapeutics has a 52-week low of $35.07 and a 52-week high of $78.08.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.